NZ534539A - 2-oxazolamines and their use as 5-HT2B receptor antagonists - Google Patents

2-oxazolamines and their use as 5-HT2B receptor antagonists

Info

Publication number
NZ534539A
NZ534539A NZ534539A NZ53453903A NZ534539A NZ 534539 A NZ534539 A NZ 534539A NZ 534539 A NZ534539 A NZ 534539A NZ 53453903 A NZ53453903 A NZ 53453903A NZ 534539 A NZ534539 A NZ 534539A
Authority
NZ
New Zealand
Prior art keywords
alkyl
optionally substituted
group
compound according
amino
Prior art date
Application number
NZ534539A
Other languages
English (en)
Inventor
Alexander William Oxford
Richard Anthony Borman
Robert Alexander Coleman
Kenneth Lyle Clark
George Hynd
Janet Ann Archer
Amanda Aley
Neil Victor Harris
Original Assignee
Pharmagene Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagene Lab Ltd filed Critical Pharmagene Lab Ltd
Publication of NZ534539A publication Critical patent/NZ534539A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ534539A 2002-02-13 2003-02-11 2-oxazolamines and their use as 5-HT2B receptor antagonists NZ534539A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203412.2A GB0203412D0 (en) 2002-02-13 2002-02-13 5-HT 2B receptor antagonists
PCT/GB2003/000552 WO2003068226A1 (en) 2002-02-13 2003-02-11 2-oxazolamines and their use as 5-ht2b receptor antagonists

Publications (1)

Publication Number Publication Date
NZ534539A true NZ534539A (en) 2006-02-24

Family

ID=9930999

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ534539A NZ534539A (en) 2002-02-13 2003-02-11 2-oxazolamines and their use as 5-HT2B receptor antagonists

Country Status (17)

Country Link
US (1) US7429607B2 (enExample)
EP (1) EP1474140B1 (enExample)
JP (1) JP4439266B2 (enExample)
KR (1) KR20040084905A (enExample)
CN (1) CN1633291A (enExample)
AU (1) AU2003207297B2 (enExample)
CA (1) CA2472762A1 (enExample)
DE (1) DE60317632T2 (enExample)
EA (1) EA200401077A1 (enExample)
GB (1) GB0203412D0 (enExample)
IL (1) IL163110A (enExample)
MX (1) MXPA04007738A (enExample)
NO (1) NO327465B1 (enExample)
NZ (1) NZ534539A (enExample)
PL (1) PL370221A1 (enExample)
WO (1) WO2003068226A1 (enExample)
ZA (1) ZA200406010B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299948B1 (it) 1998-04-02 2000-04-04 Azionaria Costruzioni Acma Spa Metodo e dispositivo per la formazione di gruppi di articoli appiattiti.
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
JP2006528617A (ja) * 2003-07-24 2006-12-21 ファーマジーン ラボラトリーズ リミテッド 5−ht2b受容体アンタゴニスト
WO2005079845A1 (ja) 2004-02-20 2005-09-01 Astellas Pharma Inc. 片頭痛予防薬
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
WO2005097113A2 (en) * 2004-04-08 2005-10-20 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
PL1797038T3 (pl) 2004-09-29 2012-11-30 Bayer Healthcare Llc Termodynamicznie trwała postać tosylanu bay 43-9006
WO2014085413A1 (en) * 2012-11-28 2014-06-05 Temple University - Of The Commonwealth System Of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators
KR101592068B1 (ko) 2013-11-08 2016-02-05 순천향대학교 산학협력단 플라즈마 아포리포프로테인 h를 포함하는 아스피린 과민성 호흡계 질환 및 아스피린 내성 천식 구별 진단용 마커 및 구별 진단용 키트
CN116789549A (zh) * 2023-06-16 2023-09-22 山东科源化工有限公司 一种羟基乙酸乙烯酯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0658559A1 (de) * 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
WO1995024200A1 (en) 1994-03-11 1995-09-14 Eli Lilly And Company Method for treating 5ht2b receptor related conditions
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
ATE227710T1 (de) * 1996-04-03 2002-11-15 Takeda Chemical Industries Ltd Oxazole derivate,ihre herstellung und verwendung
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
EP1200093B1 (en) 1999-07-30 2003-09-24 Pharmagene Laboratories Ltd Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.

Also Published As

Publication number Publication date
ZA200406010B (en) 2005-06-08
DE60317632D1 (de) 2008-01-03
JP2005528341A (ja) 2005-09-22
EP1474140A1 (en) 2004-11-10
US20040010022A1 (en) 2004-01-15
MXPA04007738A (es) 2004-10-15
US7429607B2 (en) 2008-09-30
NO327465B1 (no) 2009-07-06
EA200401077A1 (ru) 2005-06-30
KR20040084905A (ko) 2004-10-06
GB0203412D0 (en) 2002-04-03
WO2003068226A1 (en) 2003-08-21
CN1633291A (zh) 2005-06-29
EP1474140B1 (en) 2007-11-21
CA2472762A1 (en) 2003-08-21
IL163110A (en) 2010-12-30
AU2003207297A2 (en) 2003-09-04
JP4439266B2 (ja) 2010-03-24
DE60317632T2 (de) 2008-10-30
NO20043799L (no) 2004-09-10
AU2003207297A1 (en) 2003-09-04
AU2003207297B2 (en) 2008-11-06
PL370221A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
CA2532505A1 (en) 5-ht2b receptor antagonists
MX2007010401A (es) Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
KR20010079952A (ko) 인데노-, 나프토- 및 벤조사이클로헵타 디하이드로티아졸유도체, 이의 제조방법 및 식욕감퇴제로서의 이의 용도
NZ556125A (en) Pyrazine derivatives for inhibiting RAF activity
AU2004281225B2 (en) Furan derivatives as EP4 receptor antagonists
NZ534539A (en) 2-oxazolamines and their use as 5-HT2B receptor antagonists
AU2014300745A1 (en) N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
JP2006524687A (ja) バニロイド受容体で阻害活性を示す新規複素環アミド
JP2008545686A (ja) 5ht6受容体を調節する新規な8−スルホニルアミノ−3アミノ置換クロマンまたはテトラヒドロナフタレン誘導体
JPH08500101A (ja) 炎症抑制剤として有用な2−複素環−5−ヒドロキシ−1,3−ピリミジン類
JP2009505973A (ja) Ep2受容体アゴニスト
CA2472763A1 (en) 5-ht2b receptor antagonists
US20050176791A1 (en) 5-HT2B receptor antagonists
CA2525438A1 (en) Glyoxalase inhibitors
NZ572246A (en) Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
WO2005097113A2 (en) 5-ht2b receptor antagonists
MXPA05001245A (es) Nuevos derivados de cicloalcanodionas, procedimiento para su preparacion y sus aplicaciones farmacologicas.
US20230000871A1 (en) Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
EA043371B1 (ru) 1-метил-4-[(4-фенилфенил)сульфонилметил]циклогексаноловые и 1-метил-4-[[4-(2-пиридил)фенил]сульфонилметил]циклогексаноловые соединения и их терапевтическое применение
BRPI0614724A2 (pt) agonistas de receptor de ep2

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed